Skip Navigation


JAC Advance Access originally published online on July 3, 2009
Journal of Antimicrobial Chemotherapy 2009 64(3):659-660; doi:10.1093/jac/dkp231
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/3/659    most recent
dkp231v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Patel, S. N.
Right arrow Articles by Low, D. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, S. N.
Right arrow Articles by Low, D. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008

Samir N. Patel1,2, Dylan R. Pillai2,3, Sylvia Pong-Porter1, Allison McGeer1,2, Karen Green1 and Donald E. Low1,2,3,*

1 Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada 2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada 3 Ontario Public Health Laboratories, Toronto, Ontario M9P 3T1, Canada

* Corresponding author. Tel: +1-416-586-4435; Fax: +1-416-586-8746; E-mail: dlow@mtsinai.on.ca

Keywords: β-lactams , ketolides , multidrug-resistant , community-acquired pneumonia

The first 10% of the full text of this article appears below.

Sir,

Streptococcus pneumoniae is an important cause of both invasive and non-invasive infections in all age groups throughout the world. While the introduction of pneumococcal conjugate vaccine led to a decrease in invasive pneumococcal disease, multidrug-resistant (MDR) strains not belonging to serotypes included in the vaccine are now increasing and may result in treatment failures, as predicted by pharmacokinetic and pharmacodynamic parameters.1,2

Ceftobiprole and ceftaroline are newly developed . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?